Dr Scott Tagawa speaks to ecancer about data he presented at ESMO 2025 on [177Lu]Lu-PSMA-617 combined with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitor (ARPI) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Dr Tagawa reports that the PSMAddition trial demonstrated benefits with acceptable safety in this patient population with a primary endpoint of the study as radiographic progression-free survival. He comments that the study authors hope to have more details in terms of patient reported outcomes and other correlative analyses coming in the future.

See experts discuss more on prostate cancer here.